tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Moleculin Biotech receives approval for pivotal Phase 2B/3 study of Annamycin
PremiumThe FlyMoleculin Biotech receives approval for pivotal Phase 2B/3 study of Annamycin
17d ago
Moleculin Biotech Faces Nasdaq Delisting Warning
Premium
Company Announcements
Moleculin Biotech Faces Nasdaq Delisting Warning
29d ago
Moleculin Biotech price target lowered to $13 from $20 at Roth Capital
Premium
The Fly
Moleculin Biotech price target lowered to $13 from $20 at Roth Capital
29d ago
Moleculin Biotech receives FDA feedback on pediatric study plan for Annamycin
PremiumThe FlyMoleculin Biotech receives FDA feedback on pediatric study plan for Annamycin
1M ago
Moleculin Biotech announces ‘What This Means’ virtual investor segment
Premium
The Fly
Moleculin Biotech announces ‘What This Means’ virtual investor segment
2M ago
Moleculin Biotech assumed with a Buy at H.C. Wainwright
Premium
The Fly
Moleculin Biotech assumed with a Buy at H.C. Wainwright
2M ago
Morning News Wrap-Up: Wednesday’s Biggest Stock Market Stories
PremiumMarket NewsMorning News Wrap-Up: Wednesday’s Biggest Stock Market Stories
2M ago
Moleculin Biotech Reports Positive Annamycin Trial Results
Premium
Company Announcements
Moleculin Biotech Reports Positive Annamycin Trial Results
2M ago
Moleculin Biotech reports efficacy results from Phase 1B/2 trial of annamycin
Premium
The Fly
Moleculin Biotech reports efficacy results from Phase 1B/2 trial of annamycin
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100